A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

NCT05359081 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

68

Enrollment

INDUSTRY

Sponsor class

Stopped Due to company business strategy

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856

Sponsor

Sumitomo Pharma Co., Ltd.